THURSDAY, OCTOBER 5

4:30 pm  WELCOME
Mark Johnson, MD, President
Joan Miller, MD

RETINAL VASCULAR DISEASE
PRESIDING OFFICER: Jennifer Lim, MD
MODERATOR: Matthew MacCumber, MD

4:40  Intravitreal Inhibition of Runx1 Reduces Pathologic Retinal Angiogenesis
Leo Kim, MD

4:45  New Insights in Vancomycin-associated Hemorrhagic Occlusive Retinal Vasculopathy (HORV)
Bozho Todorich, MD

4:50  Patient Safety Data Across Clinical Trials Using Suprachoroidal Injection of Triamcinolone Acetonide
Seenu Hariprasad, MD

4:55  Area Under the Curve (AUC) Analysis of Visual Outcomes with the Fluocinolone Acetonide Implant and Ranibizumab with Deferred Laser Over 36 Months
Craig Greven, MD

5:00  Results of the SCORE2 Randomized Non-inferiority Trial Evaluating Effect of Bevacizumab versus Aflibercept on Visual Acuity among Patients with Macular Edema due to Central Retinal Vein Occlusion
Ingrid Scott, MD

5:06  DISCUSSION

5:09  A 24-Week Multi-center, Single-blind, Prospective, Stratified and Randomized Study of the Effects of Bevacizumab (BVB)—Dexamethasone-DDS (Dex-DDS) for the Treatment of Non-ischemic Central Retinal Vein Occlusion (CRVO): The OZAB Study Group
Karl Csaky, MD

5:15  DISCUSSION

5:18  Effect of Topical Dorzolamide-Timolol on Macular Edema in Eyes Receiving Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Retinal Vein Occlusion: A Pilot Study
Jason Hsu, MD

5:24  DISCUSSION

5:27  *Intravitreal Injection using 33-gauge Versus 30-gauge Needles: Comparison of Patients’ Experience
Allen Chiang, MD

5:33  *The Real World Effect of Intravitreous Anti-VEGF Drugs on IOP
Matthew MacCumber

5:39  *Effect of Needle Size on Immediate Post-injection IOP and on Late Onset Ocular Hypertension
Bernard Doft, MD
5:45 pm  *DISCUSSION OF PREVIOUS 3 PAPERS

5:48  *Prevalence of Retinopathy in Patients with Sickle Cell Disease
Adrienne Scott, MD

5:54  *Longitudinal Study of Spectral Domain Optical Coherence Tomography of Sickle Cell Retinopathy Eyes: Prevalence of Thinning and Systemic Disease Associations
Jennifer Lim, MD

6:00  *DISCUSSION OF PREVIOUS 2 PAPERS

RETINAL DYSTROPHIES AND DEGENERATIONS
PRESIDING OFFICER: David Zacks, MD, PhD
MODERATOR: Ninel Gregori, MD

6:03  Hyperreflective Foci in Stargart Disease
Francesco Bandello, MD

6:08  North Carolina Macular Dystrophy (NCDR1): Mutations Found Affecting the Retinal Transcription Factor PRDM13 in Twelve Additional Families
Kent Small, MD

6:13  *Retinal Anatomy and Electrode Array Positioning in Retinitis Pigmentosa Patients after Argus II Implantation
Ninel Gregori, MD

6:19  *Intraoperative OCT during Argus II Implantation in the DISCOVER Study
Aleksandra Rachitskaya, MD

6:25  *DISCUSSION OF PREVIOUS 2 PAPERS

6:28  *Rod Outer Segment (OS) Loss Causes Glucose Starvation of Cones in Retinitis Pigmentosa (RP)
Henry Kaplan, MD

6:34  *Effects of Neuroprotection on Photoreceptor Precursor Transplantation in Mice
Demetrios Vavvas, MD

6:40  *DISCUSSION OF PREVIOUS 2 PAPERS

6:43  ADJOURN

PEDIATRIC RETINAL DISEASE
PRESIDING OFFICER: Antonio Capone, MD
MODERATOR: Mary Elizabeth Harnett, MD

7:30 am  27-gauge Vitrectomy for Pediatric Vitreoretinopathies
Yoshihiro Yonekawa, MD

7:35  Multicenter Study of Pediatric Macular Holes: Surgical Outcomes with Microincisional Vitrectomy Surgery
Audina Berrocal, MD
7:40 am  Conceptual and Technological Advances in Plus Disease Diagnosis in Retinopathy of Prematurity  
Peter Campbell, MD

7:45  Innovative Experimental Model to Detect Protective Factors against Retinopathy of Prematurity  
Mary Elizabeth Hartnett, MD

7:51  DISCUSSION

7:54  Foveal Development as Visualized on Spectral Domain Optical Coherence Tomography and Visual Acuity Development in Preterm Infants  
Lejla Vajzovic, MD

8:00  DISCUSSION

8:03  Increased Choriocapillaris Vessel Density in Amblyopic Children  
Irena Tsui, MD

8:09  DISCUSSION

**HISTORICAL SYMPOSIUM**

**Retina and The Retina Society**

*Where Have We Been and Where Are We Going?*

8:15  Introduction  
Mark Johnson, MD

8:20  The Retina Society: History and Significance  
Bradley Straatsma, MD; Alice McPherson, MD

8:35  Introduction of Charter Members and Past Presidents  
Mark Johnson, MD

8:50  Highlights of the Last 50 Years in Medical Retina  
Lee Jampol, MD

9:10  Highlights of the Last 50 Years in Surgical Retina  
Kirk Packo, MD

9:30  Retina in the Next 50 Years  
Mark Blumenkranz, MD

9:45  QUESTIONS/PANEL DISCUSSION

10:00  REFRESHMENT BREAK/EXHIBITS

**AGE-RELATED MACULAR DEGENERATION I**

**PRESIDING OFFICER:** Allen Ho, MD  
**MODERATOR:** Joan Miller, MD

10:30  Understanding the Natural History of Geographic Atrophy Secondary to Age-related Macular Degeneration: Baseline Data from Proxima A  
John Wells, MD

10:35  Phase 1/2A Study of OPT-302, an Inhibitor of Vascular Endothelial Growth Factors C and D (VEGF-C/D ‘Trap’), Alone and In Combination with Ranibizumab, for Neovascular Age-related Macular Degeneration  
Pravin Dugel, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 10:40 am | Bevacizumab Injection in Patients with Neovascular Age-related Macular Degeneration Increases Angiogenic Biomarkers  
*Luiz Lima, MD, PhD* |
| 10:45  | Pharmacokinetic Study of Intravitreal Aflibercept in Humans with Neovascular Age-related Macular Degeneration  
*Diana Do, MD* |
| 10:50  | Long Term Follow-up of Cell Therapy for Geographic Atrophy Phase 1/2a Study: 24 Month Results and Evolution of a Surgical Delivery Program  
*Allen Ho, MD* |
| 10:56  | DISCUSSION  |
| 10:59  | Nuclear DNA Damage in Retinal Pigment Epithelium Promotes Senescence and Inflammation in Age-related Macular Degeneration  
*Joan Miller, MD* |
| 11:05  | DISCUSSION  |
| 11:08  | Disease Expression in Non-exudative Age-related Macular Degeneration Varies with Choroidal Thickness  
*Richard Spaide, MD* |
| 11:14  | DISCUSSION  |
| 11:17  | Swept Source OCT Angiographic Prevalence, Incidence, and Natural History of Subclinical Neovascularization in Age-related Macular Degeneration  
*Philip Rosenfeld, MD, PhD* |
| 11:23  | DISCUSSION  |
| 11:26  | The Evolution of the Plateau, an Optical Coherence Tomography Signature Seen in Geographic Atrophy  
*Bailey Freund, MD* |
| 11:32  | DISCUSSION  |
| 11:35  | INVITED PRESENTATION  |
| 11:35  | Big Data in Ophthalmology: The Promise and Perils  
*David Parke II, MD*  
Executive Vice President and CEO, American Academy of Ophthalmology |
| 11:45  | FELLOWSHIP RESEARCH AWARD PRESENTATION  |
| 11:45  | INTRODUCTION: David Zacks, MD  
Inner Choroidal Changes in Acute Macular Neuroretinopathy (AMN): Insights via Optical Coherence Tomography Angiography (OCTA) and Correlation with Multimodal Imaging  
*Sun Young Lee, MD* |
| 12:00 pm | RETINA RESEARCH AWARD OF MERIT — Charles L. Scopes Lecture  
INTRODUCTION: Emily Chew, MD  
Genetics and Age-related Macular Degeneration  
*Michael Klein, MD* |
| 12:30 – 1:00 | LUNCH FOR ATTENDEES AND EXHIBITORS  |
| 1:00 – 2:00 | DESSERT AND POSTER SESSION I — Ballroom Foyer |
INFLAMMATION
PRESIDING OFFICER: Harry Flynn Jr, MD
MODERATOR: Douglas Jabs, MD, MBA

2:00 pm  The Role of Cystoid Macular Edema as a Marker in the Progression of Non-paraneoplastic Autoimmune Retinopathy
Avni Finn, MD, MBA

2:05  Characteristics of Endogenous Endophthalmitis Managed at an Outpatient Tertiary Care Referral Clinic
Andrew Moshfeghi, MD, MBA

2:10  Early Post-treatment Changes in Choroidal Circulation to Alert Sunset Glow Fundus Appearance in Vogt-Koyanagi-Harada Disease
Susumu Ishida, MD, PhD

2:15  An Intravitreal Injection Protocol to Reduce the Risk of Post-injection Endophthalmitis
Joshua Levinson, MD

2:21 DISCUSSION

2:24  A Concern for Vitreoretinal Surgeons: A Decreasing Trend of Susceptibility to Vancomycin and Fluoroquinolones among Coagulase-negative Straphylococcus (CONS) Causing Endophthalmitis
Harry Flynn Jr, MD

2:30 DISCUSSION

2:33  Fluocinolone Acetonide Implant versus Systemic Therapy for Uveitis: Seven-year Results: The Multicenter Uveitis Steroid Treatment (MUST) Trial
Douglas Jabs, MD, MBA

2:39 DISCUSSION

2:42  *Improvement in Visual Acuity in Subjects with Active Non-infectious Uveitis of the Posterior Segment and Low Baseline Vision Receiving Intravitreal Sirolimus: Results of the SAKURA Program
Quan Dong Nguyen, MD, MSc

2:48  *Results of the SAKURA Program: Central Retinal Thickness Changes with Intravitreal Sirolimus in Subjects with Non-infectious Uveitis of the Posterior Segment and Macular Edema at Baseline
Peter Kaiser, MD

2:54  *DISCUSSION OF PREVIOUS 2 PAPERS

2:57  New Insights in Congenital Zika Syndrome
Mauricio Maia, MD, PhD

3:03 DISCUSSION

3:06 REFRESHMENT BREAK/EXHIBITS
IMAGING

PRESIDING OFFICER: Julia Haller, MD
MODERATOR: David Brown, MD

3:36 pm  In Vivo Assessment of Scleral Deformability in Highly Myopic Eyes
Quan Hoang, MD

3:41  Diabetic Choroidopathy using Swept-source OCT
John Miller, MD

3:46  Pilot Study of Doppler Optical Coherence Tomography Based Flowmeter in Eyes with Retinal Diseases
Akitoshi Yoshida, MD, PhD

3:51  Adaptive Optics for Monitoring Retina Disease
Thomas Friberg, MD

3:56  Choroid and Optic Nerve Changes Associated with Long-term Space Flight
David Brown, MD

4:01  Quantitative Optical Coherence Tomography Angiography of the Retinal Microvasculature and the Choriocapillaris in Myopic Eyes
David Sarraf, MD

4:07  DISCUSSION

4:10  Artificial Intelligence in the Management of Macular Disease
Ursula Schmidt-Erfurth, Prof. Dr.

4:16  DISCUSSION

4:19  *Quantitative Analysis of Three Distinct Retinal Capillary Plexuses in Healthy Eyes using Optical Coherence Tomography Angiography
Sean Garrity, MD

4:25  *Retinal Vessel Density: A Comparison Across Optical Coherence Tomography Angiography (OCTA) Devices in Healthy Eyes
Nadia Waheed, MD, MPD

4:31  *DISCUSSION OF PREVIOUS 2 PAPERS

4:34  Optical Coherence Tomography Angiographic Perfusion Deviation Mapping—A Standardized Approach to Grading Vascular Defects
Richard Rosen, MD

4:40  DISCUSSION

4:43  Optical Coherence Tomography Angiography in Pachychoroidal Disease Demonstrates Inner Choroidal Flow Signal Attenuation
Orly Gal-Or, MD

4:49  DISCUSSION

4:52  Retinal Flow Density by OCTA is Useful for Detection of Nonperfused Areas in Diabetic Retinopathy
Shintaro Nakao, MD, PhD

4:58  DISCUSSION

5:01  Quality and Utility of a Portable Anterior Segment and Non-mydriatic Fundus Camera Linked to a Smartphone-based Virtual Consultation Platform
Melissa Sieber, MD
OTHER MACULAR DISEASE

PRESIDING OFFICER: Mark Johnson, MD
MODERATOR: Stanley Chang, MD

7:30 am  
Association of Irregular Pigment Epithelial Detachment in Central Serous Chororetinopathy with Genetic Variants Implicated in Age-related Macular Degeneration  
Kyu Hyung Park, MD

7:35  
Sustained Release of a Protein Therapeutic from Microporous Thin Film Polymer Devices In Vitro and in Non-human Primate Eyes  
Robert Bhistikul, MD, PhD

7:40  
Optical Coherence Tomography Angiography Features of Polypoidal Choroidal Vasculopathy and its Correlation with Indocyanine Green Angiography  
Louis Lim, MBBS

7:45  
Five-year Outcomes following Surgical Intervention for Symptomatic Epiretinal Membrane: Impact of Internal Limiting Membrane Peeling and Prior Rhegmatogenous Retinal Detachment  
Harris Sultan, MS, MD

7:50  
Microcystic Macular Changes in Association with Idiopathic Epiretinal Membranes: Clinical and Surgical Insights  
Jean-Pierre Hubschman, MD

7:56  
DISCUSSION

7:59  
Internal Limiting Membrane Dehiscence Visualized with Multicolor Scanning Laser Ophthalmoscopy is Associated with Inner Retinal Abnormalities on Optical Coherence Tomography in Eyes with Epiretinal Membrane  
Jeffrey Gross, MD

8:05  
DISCUSSION

8:08  
*Presence of Epiretinal Proliferation Affects Visual Outcomes after Surgical Repair of Full-thickness Macular Holes and Lamellar Holes  
Esther Kim, MD

8:14  
*Surgical Outcomes of Lamellar Macular Holes  
Stanley Chang, MD

8:20  
*DISCUSSION OF PREVIOUS 2 PAPERS

8:23  
Ranibizumab Treatment Provides Significant Vision Gains in Patients with Myopic Choroidal Neovascularization: Results from the Phase III RADIANCE Trial  
Paul Hahn, MD, PhD

8:29  
DISCUSSION
Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for Age-related Macular Degeneration: One-year Outcomes
Ajay Kuriyan, MD

DISCUSSION

*Vitreomacular Traction Treated by Pars Plana Vitrectomy
Marcio Nehemy

*Pneumatic Vitreolysis in Cases of Symptomatic Vitreomacular Traction With or Without Macular Holes
Jorge Arroyo, MD

*Management of Vitreomacular Traction With or Without Stage-2 Macular Holes with Pneumatic Vitreolysis
Clement Chan, MD

DISCUSSION OF PREVIOUS 3 PAPERS

*Ultra-widefield Optical Coherence Tomography Method to Advance the Visualization of Posterior Staphylomas and Accompanying Vitreoretinal Changes in Pathologic Myopia
Kyoko Ohno-Matsui, MD, PhD

*A Novel Classification of Progressive Myopia into Anterior and Posterior Subtypes
Darius Moshfeghi, MD

DISCUSSION OF PREVIOUS 2 PAPERS

Mitogen-activated Protein Kinase (MEK) Inhibitor-associated Retinopathy: Difference from Central Serous Chorioretinopathy
Jasmine Francis, MD, FACS

DISCUSSION

Best Surgical Technique and Outcomes for Large Macular Holes Determined by Real World Data
Taiji Sakamoto, MD, PhD

*The Internal Limiting Membrane Texas Taco for Closure of Large Chronic Full Thickness Macular Holes
James Major, MD

DISCUSSION OF PREVIOUS 2 PAPERS

REFRESHMENT BREAK/EXHIBITS

Free Patient Website for Visually Impaired
Yale Fisher, MD

Systemic Risk of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Neovascular Age-related Macular Degeneration in Routine Clinical Practice: A Propensity-matched Cohort Study
Andrew Barkmeier, MD
10:21 am  
*Extended Release of Bioactive Aflibercept from a Biodegradable Microsphere-hydrogel Ocular Drug Delivery System*

**Jennifer Kang-Mieler, PhD**

10:26  
A Phase 2 Study (EMERGE) of Intravitreal Administration of ICON-1 in Patients with Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

**Brian Berger, MD**

10:32  
**DISCUSSION**

10:35  
Intravitreal Rinucumab PLUS Aflibercept in Neovascular Age-related Macular Degeneration (nAMD): The CAPELLA Study

**Jeffrey Heier, MD**

10:41  
**DISCUSSION**

10:44  
Development of a Novel Intravitreal Gene Therapy Treatment for Wet Age-related Macular Degeneration

**Szilard Kiss, MD**

10:50  
**DISCUSSION**

10:53  
Effect of IOP-lowering Medications on Neovascular Age-related Macular Degeneration Treatment Outcomes in the Comparison of Age-related Macular Degeneration Treatment Trials (CATT)

**Ehsan Rahimy, MD**

10:59  
**DISCUSSION**

11:02  
Ten-year Outcomes of Eyes Receiving Continuous, Fixed-interval Dosing of Anti-vascular Endothelial Growth Factor Agents for Neovascular Age-related Macular Degeneration

**Ivan Suner, MD**

11:08  
**DISCUSSION**

11:11  
*Prevalence of Polypoidal Choroidal Vasculopathy (PCV) in Wet Age-related Macular Degeneration Eyes with and without Anti-VEGF Resistance and Diagnostic Imaging of PCV with En-face Optical Coherence Tomography (OCT) and OCT Angiography

**Gregg Kokame, MD, MMM**

11:17  
*Evaluation of Polyps and Branching Vascular Network using Indocyanine Green Angiography in the EVEREST II Study

**Colin Tan, MBBS, FRCSed (ophth)**

11:23  
*DISCUSSION OF PREVIOUS 2 PAPERS*

11:26  
**RAYMOND R. MARGHERIO AWARD PRESENTATION**

**INTRODUCTION:** David Zacks, MD, PhD

Real World Vision in Age-related Macular Degeneration Patients Treated with Bevacizumab, Ranibizumab or Aflibercept only Over One Year in a Cohort of the IRIS Registry

**Prethy Rao, MD**

11:41  
**J. DONALD M. GASS AWARD**

**INTRODUCTION:** Julia Haller, MD

Clinical Perspectives of Our Progress over the Last 40 Years in Management of Age-related Macular Degeneration

**Lawrence Singerman, MD**
ANNUAL BUSINESS MEETING — THE RETINA SOCIETY

LUNCH FOR ATTENDEES AND EXHIBITORS

DESSERT AND POSTER SESSION II — Ballroom Foyer

SURGERY I

PRESIDING OFFICER: Charles Barr, MD

MODERATOR: Jonathan Prenner, MD

Mario Romano, MD, PhD

2:20 New Instrumentation for Easy and Safe Microscopic Small Buckle Surgery in Selected Retinal Detachments
Susanne Binder, MD

2:25 Small Gauge Diabetic Vitrectomy
Charles Barr, MD

2:30 Non-infectious Severe Inflammation following Intra-operative Indocyanine Green
Howard Fine, MD, MHSc

2:35 A Prospective, Randomized Trial Comparing Plain Gut to Polyglactin 910 (Vicryl) Sutures for Sclerotomy Closure after 23-gauge Pars Plana Vitrectomy
Sunir Garg, MD

2:41 DISCUSSION

2:44 *A Novel Technique for Intraocular Lens Fixation using Gor-Tex Suture and Vitreoretinal Instrumentation: Outcomes and Imaging
Omesh Gupta, MD

2:50 *A Novel Technique for Intraocular Lens Fixation
Jonathan Prenner, MD

2:56 *Surgical Outcomes and Structural Analysis of Sutureless Intracocular Fixation of Secondary Intraocular Lenses
Jeremy Wolfe, MD, MS

3:02 *DISCUSSION OF PREVIOUS 3 PAPERS

3:05 Opacified Hydrophilic Intraocular Lenses after Pars Plana Vitrectomy and Injection of Intraocular Gas
Ayala Pollack, MD

3:11 DISCUSSION

3:14 27-gauge Pars Plana Vitrectomy for Posterior Segment Disease: Long Term Visual Outcomes and Safety Profile in 371 Eyes
Ali Khan, MD

3:20 DISCUSSION

3:23 Long-term Safety and Efficacy of Limited Vitrectomy for Clinically Significant Vitreous Floaters
Jerry Sebag, MD, FACS

3:29 DISCUSSION

3:32 REFRESHMENT BREAK/EXHIBITS
SURGERY II AND LATE BREAKING PAPERS

PRESIDING OFFICER: Bernard Doft, MD
MODERATOR: Elliott Sohn, MD

4:00 pm  Augmented Reality Video Microscope as Platform for Retina Surgery
          Adiel Barak, Prof.

4:06 DISCUSSION

4:09 Pars Plana Vitrectomy (PPV) Alone for Management of Phakic
       Rhegmatogenous Retinal Detachment (RRD) with Inferior Breaks
       Katherine Talcott, MD

4:15 DISCUSSION

4:18 Posteriorly Inserted Vitreous Base: Clinical Features and Outcomes
       Elliott Sohn, MD

4:24 DISCUSSION

4:27 *Outcomes of Current Techniques for Repair of Primary Pseudophakic
       Rhegmatogenous Retinal Detachment (RRD)
       Daniel Joseph, MD

4:33 *Outcomes of Current Techniques for Repair of Moderately Complex
       Phakic Rhegmatogenous Retinal Detachment
       Edwin Ryan, MD

4:39 *DISCUSSION OF PREVIOUS 2 PAPERS

4:42 *A Comparison of Quality-of-life Gains from Vitreoretinal and Systemic
       Healthcare Interventions
       Gary Brown, MD, MBA

4:48 *Cost-utility Evaluation of Posterior Vitreous Detachment and
       Prophylaxis of Retinal Detachment
       William Smiddy, MD

4:54 *DISCUSSION OF PREVIOUS 2 PAPERS

LATE BREAKING PAPERS

4:57 Results of the Phase 2 Trial of Ciliary Neurotrophic Factor for Macular
       Telangiectasia Type 2
       Emily Chew, MD

5:03 DISCUSSION

5:06 Phase 2 Tolerability and Effects of ALK-001 in Stargardt Disease
       (“TEASE” Trial): An Update
       Christine Kay, MD

5:12 DISCUSSION

5:15 Ozurdex vs Ranibizumab vs Combination for Central Retinal Vein
       Occlusion (ORION) Study
       Victor Gonzalez, MD

5:21 DISCUSSION

5:24 ADJOURN
**DIABETIC RETINOPATHY**

**PRESIDING OFFICER:** Glenn Jaffe, MD  
**MODERATOR:** Shlomit Schaal, MD

7:30 am  
*Impact of Baseline Macular Perfusion on Visual and Anatomic Outcomes during DME Management: Analysis of the VISTA Phase 3 Study*  
Chirag Shah, MD, MPH

7:35  
*Role of Angiopoietin-2 in Retinal Microvascular Inflammation in Diabetic Retinopathy*  
Arup Das, MD, PhD

7:40  
*Real World U.S. Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema*  
Thomas Ciulla, MD, MBA

7:45  
*Correlation of Response between Both Eyes to First and Second Line Anti-VEGF Therapy in Diabetic Macular Edema*  
Itay Chowers, MD

7:50  
*Diabetic Microaneurysm Wall Characteristics on Adaptive Optics Scanning Laser Ophthalmoscopy (AOSLO) and Longitudinal Changes in the Perfusion and Local Neuroretinal Pathology*  
Jennifer Sun, MD

7:55  
*Early Automatic Detection of Minute Microvasculature Changes in Diabetic Patients Using a Novel Algorithm that Analyzes Optical Coherence Tomography Angiography Images of the Retina*  
Shlomit Schaal, MD

8:00  
*Induction of Autoantibodies to Retinal Proteins with Panretinal Photocoagulation in Patients with Diabetic Retinopathy*  
Tongalp Tezel, MD

8:05  
*Identification of Novel Genes Required for Eye Function by Coordinated and Systematic Genome-wide Screening of Mouse Knockouts*  
Ala Moshiri, MD

8:10  
*Real World Outcomes with the Fluocinolone Acetonide (FAc) 0.2 g/day Implant for Diabetic Macular Edema: The USER Study*  
Christopher Riemann, MD

8:16  
DISCUSSION

8:19  
*Early Pars Plana Vitrectomy versus Laser Treatment for Diabetic Retinopathy Complications: Eight Year Visual Acuity Outcomes in Two Age Groups*  
Maria Berrocal, MD

8:25  
DISCUSSION

8:28  
*Endolaserless Vitrectomy with Intravitreal Aflibercept Injection (IAI) for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage (LASER LESS TRIAL)*  
Dennis Marcus, MD

8:34  
DISCUSSION
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:37 am | Baseline Factors Associated with Greater than or Equal to 2-Step DR Severity Improvement with Ranibizumab  
          **Dilsher Dhoot, MD** |
| 8:43 | DISCUSSION |
| 8:46 | *Persistent Macular Thickening following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Center-involved Diabetic Macular Edema with Vision Impairment  
          **Kevin Blinder, MD** |
| 8:52 | *Poorer Anatomic Response to Anti-VEGF Therapy among DME Patients is Associated with Less Vision Improvement: A Post-hoc Analysis of Protocol I  
          **Nancy Holekamp, MD** |
| 8:58 | DISCUSSION OF PREVIOUS 2 PAPERS |
| 9:01 | Plasma VEGF Concentrations after Intravitreous Anti-VEGF Therapy for Diabetic Macular Edema during the DRCR.net Protocol-T  
          **Charles Wykoff, MD, PhD** |
| 9:07 | DISCUSSION |
| 9:10 | Comparison of Follow-up Compliance Rates Between Pan-retinal Photocoagulation and Intravitreal Injections in Patients with Proliferative Diabetic Retinopathy  
          **Anthony Obeid, MD** |
| 9:16 | DISCUSSION |
| 9:19 | Panretinal Photocoagulation versus Ranibizumab for Proliferative Diabetic Retinopathy: Comparison of Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial  
          **Glenn Jaffe, MD** |
| 9:25 | DISCUSSION |
| 9:28 | Distribution of Nonperfusion Area on Ultra-Widefield Fluorescence Angiography in Eyes with Diabetic Macular Edema: DAVE Study  
          **SriniVas Sadda, MD** |
| 9:34 | DISCUSSION |
| 9:37 | *The Radial Peripapillary Capillary Plexus and the Pathophysiology of Diabetic Retinopathy  
          **Edoardo Midena, MD, PhD** |
| 9:43 | *Optical Coherence Tomography Angiography for Diabetic Retinopathy: Importance of Evaluating Three Macular Capillary Networks  
          **Amani Fawzi, MD** |
| 9:49 | DISCUSSION OF PREVIOUS 2 PAPERS |
| 9:52 | Assessing the Cardiovascular and Cerebrovascular Safety Profile of Ranibizumab for the Treatment of Diabetic Macular Edema: A Pooled Analysis  
          **Marco Zarbin, MD** |
| 9:58 | DISCUSSION |
| 10:01 | REFRESHMENT BREAK/EXHIBITS |
TUMORS

PRESIDING OFFICER: Timothy Murray, MD
MODERATOR: Ivana Kim, MD

10:30 am  Panoramic Fluorescein and ICG Angiography in Choroidal Melanoma: A Statistical Analysis and Therapeutic Implications
Leonidas Zografos, MD

10:35  Indications and Outcomes of Vitrectomy in Patients Treated with Proton Irradiation for Choroidal Melanoma
Ivana Kim, MD

10:40  Diagnostic Yield of Prognostication Biopsy for Uveal Melanoma
Arun Singh, MD

10:45  Correlation of Cytogenic Abnormalities with Clinical Features of Uveal Melanoma in 1059 Patients
Carol Shields, MD

10:51  DISCUSSION

10:54  *Association Between Traditional Clinical High-risk Features and Gene Expression Profile Classification in Uveal Melanoma
Amy Schefler, MD

11:00  *Is Discriminant Score Associated with GEP Class in Decision DX-UM test Important Prognostically?
James Augsburger, MD

11:06  *Correlation of Gene Expression Profile Status and American Joint Commission on Cancer (AJCC) Stage in Uveal Melanoma: A Multicenter Study
Prithvi Mruthyunjaya, MD

11:12  *DISCUSSION OF PREVIOUS 3 PAPERS

11:15  Peering into the Past with Next Generation Sequencing: New Insights into the Origins and Metastatic Propensity of Uveal Melanoma
William Harbor, MD

11:21  DISCUSSION

11:24  *Prospective, Randomized Evaluation of Aflibercept for Radiation Maculopathy—One-year Interim Analysis
Timothy Murray, MD

11:30  *EDI-OCT and OCTA Findings in Radiation Maculopathy following Treatment of Uveal Melanoma
William Mieler, MD

11:36  *DISCUSSION OF PREVIOUS 2 PAPERS

11:39  Invisible Intraocular Tumors: Detection with Multimodal Imaging
Jerry Shields, MD

11:45  DISCUSSION

11:48  The Expanding Use of Intravitreal Melphalan in Retinoblastoma
David Abramson, MD

11:54  DISCUSSION
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:57 am</td>
<td>Proton Beam Therapy for Patients with Recurrent Uveal Melanoma&lt;br&gt;Evangelos Gragoudas, MD</td>
</tr>
<tr>
<td>12:03 pm</td>
<td>DISCUSSION</td>
</tr>
<tr>
<td>12:06</td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>